PARP3
Protein mono-ADP-ribosyltransferase PARP3
As of the edition of 20 October 2026, PARP3 (protein mono-ADP-ribosyltransferase PARP3, UniProt Q9Y6F1) has 5 drugs tested at it and 7 companies on the list, 3 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q9Y6F1
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 16
- Disease areas
- Cancer; Urinary and reproductive; Pregnancy and women's health; Hormones; Skin and connective tissue; Digestive system; Lungs and airways; Blood and lymph
- Registered trials of its drugs
- 575
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 2 |
| Went quiet | 1 |
| Stopped | 2 |
| Total | 5 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Olaparib | Marketed | Phase 4 | Ends 2028 |
| Veliparib | Stopped | Phase 3 | none listed |
| Rucaparib | Marketed | Phase 3 | Ends 2031 |
| AZD2461 | Went quiet | Phase 1 | none listed |
| E-7016 | Stopped | Phase 2 | none listed |
5 of 5 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 3 |
| Route B | 2 |
| Undetermined | 2 |
| Total on the list | 7 |
| Company | Route |
|---|---|
| AstraZeneca | Route B |
| AbbVie | Route A |
| Eisai | Route A |
The other 4 companies at PARP3
In the product7 companies in all; 4 are not named here, and no score is.
See the 7 companies at PARP3, ranked, with the facts behind eachRequest access. Nothing is shown until you do.